Preoperative stereotactic radiosurgery for patients with 1–4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694)

Author:

Agrawal Namita1,Shireman Jack M2ORCID,Shiue Kevin1,Kamer Aaron3,Boyd LaKeisha4,Zang Yong4ORCID,Mukherjee Neel2,Miller James5,Kulwin Charles6,Cohen-Gadol Aaron5,Payner Troy6,Lin Chih-Ta5,Savage Jesse J5,Lane Brandon5,Bohnstedt Bradley5,Lautenschlaeger Tim1,Saito Naoyuki1,Shah Mitesh5,Watson Gordon1,Dey Mahua2ORCID

Affiliation:

1. Department of Radiation Oncology, Indiana University School of Medicine , Indianapolis, Indianapolis , USA

2. Department of Neurosurgery, University of Wisconsin Madison School of Medicine and Public Health , Madison, Wisconsin , USA

3. Department of Clinical Radiology and Imaging Sciences, Indiana University School of Medicine , Indianapolis, Indianapolis , USA

4. Department of Biostatistics and Health Data Science, Indiana University School of Medicine and Richard M. Fairbanks School of Public Health , Indianapolis, Indianapolis , USA

5. Department of Neurological Surgery, Indiana University School of Medicine , Indianapolis, Indianapolis , USA

6. Goodman Campbell Brain and Spine Neurological Surgery , Indianapolis, Indianapolis , USA

Abstract

Abstract Background Stereotactic radiosurgery (SRS) following surgical resection is the standard of care for patients with symptomatic oligo brain metastasis (BM), however, it is associated with 10–15% local failure. Targeting a resection cavity is imprecise, thus preoperative radiosurgery where the target is well-defined may be superior, however, the efficacy of preoperative SRS has not yet been tested in a clinical trial. Methods We conducted a phase 2, single-arm trial of preoperative SRS followed by surgical resection in patients with 1–4 symptomatic oligo BMs (NCT03398694) with the primary objective of measuring 6-month local control (LC). SRS was delivered to all patients utilizing a gamma knife or linear accelerator as per RTOG-9005 dosing criteria [Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291–298] based on tumor diameter with the exception that the largest lesion diameter treated was 5 cm with 15 Gy with all SRS treatment given in single fraction dosing. Results The trial screened 50 patients, 48 patients were treated under the protocol and 32 patients completed the entire follow-up period. Of all the patients who completed the follow-up period, the primary endpoint of 6-month LC was 100% (95% CI: 0.891–1.000; P = .005). Secondary endpoints, presented as medians, were overall survival (17.6 months), progression-free survival (5.3 months), distant in-brain failure (40.8% at 1 year), leptomeningeal failure (4.8% at 1 year), and radiation necrosis (7.7% at 1 year). Conclusions Our data confirms superior local control in patients who received preoperative SRS when compared to historical controls. Further study with a larger randomized cohort of patients is warranted to fully understand the benefits of preoperative SRS.

Funder

IU Value Research grant

National Institutes of Health

National Institute of Neurological Disorders and Stroke

Publisher

Oxford University Press (OUP)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3